...same title at Merrimack Pharmaceuticals Inc. (NASDAQ:MACK). Sager will become a consultant to the company.Women’s health company Agile Therapeutics Inc....
...from Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS), where he was EVP of technical operations. Robin Sawka Swedish Orphan Biovitrum AB Ikena Oncology Agile Therapeutics Inc. Nordic...

...Solna, Sweden) hired Scott Coiante as SVP and CFO. He was SVP and CFO of Agile Therapeutics Inc....

...become VP, head of drug safety and pharmacovigilance. Garner was CMO, SVP clinical development at Agile Therapeutics Inc....

...see "LifeArc Gets $1.3B for Keytruda Royalties" ). FDA committee sets date for Agile's Twirla Agile Therapeutics Inc....
...lambrolizumab) lebrikizumab (MILR1444A, RG3637, tnx-650, anti-IL13) Ryaltris, mometasone/olopatadine (gsp 301) Seven-day contraceptive patch, Twirla (AG200-15, ag-200-15, Agile Patch, estradiol/levonorgestrel) Agile Therapeutics Inc. Almirall...

...for Dsuvia sufentanil sublingual tablet (ARX-04) to treat moderate-to-severe acute pain in medically supervised settings Agile Therapeutics Inc....

...levonorgestrel. Agile Therapeutics Inc. (NASDAQ:AGRX), Princeton, N.J. Product: Twirla (seven-day contraceptive patch, AG200-15) Business: Endocrine/Metabolic Mary Romeo AG200-15 Seven-day contraceptive patch Twirla Agile Therapeutics Inc. Estrogen...

...FDA and identify a path for Twirla's approval. Twirla delivers low-dose ethinyl estradiol and levonorgestrel. Mary Romeo AG200-15 Twirla Agile Therapeutics Inc....

...CSE:ZEAL; NASDAQ:ZEAL) 8/9/17 $89.9 $548.9 $589.8 7% MyoKardia Inc. (NASDAQ:MYOK) 8/8/17 $142.9 $1,260.8 $1,521.8 21% Agile Therapeutics Inc....

...Agile Therapeutics Inc. (NASDAQ:AGRX), Princeton, N.J. Product: Twirla (seven-day contraceptive patch, AG200-15) Business: Endocrine/Metabolic Elizabeth S. Eaton AG200-15 Seven-day contraceptive patch Twirla Agile Therapeutics Inc. Estrogen...

...for the product. This quarter, Agile plans to resubmit an NDA to FDA for Twirla. Agile Therapeutics Inc....
...as measured by the Pearl Index; safety Status: Phase III data Milestone: Resubmit NDA (2Q17) Chris Lieu AG200-15 Twirla Agile Therapeutics Inc. Estrogen...